MedTrace Logo

FESPET Study: Female EStrogen recePtor in Endometrial Cancer Treatment

NCT03489473 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2019-04-18

No results posted yet for this study

Summary

Endometrial cancer is the most common gynecological malignancy in the western world and its incidence is expected to increase in the coming years due to obesity. Major treatment modalities include surgery, radiotherapy and chemotherapy. Hormonal therapy can be considered in primary treatment if other treatment modalities are not feasible and in treatment for recurrent disease. Hormonal treatment has shown to be more effective in endometrial cancers expressing estrogen (ER) and progesterone receptor (PR). Tumor heterogeneity frequently causes loss of expression of ER and PR in metastasis compared to primary tumors. The FES PET CT scan combines PET-CT scan with an estrogen tracer, thus allowing non invasive visualisation of estrogen receptor, even in patients with metastasis that are difficult to reach for biopsy. FES PET has been shown to relate well to ER expression and to treatment response in breast cancer. This study explores the feasibility of the FES PET scan in endometrial cancer patients.

Conditions

Interventions

DIAGNOSTIC_TEST

18F-FES PET CT scan

PET CT scan with estrogen tracer

Sponsors & Collaborators

  • Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

    collaborator OTHER

  • University Medical Center Groningen

    collaborator OTHER

  • Haukeland University Hospital

    collaborator OTHER

  • Radboud University Medical Center

    lead OTHER

Principal Investigators

  • JMA Pijnenborg, MD, PhD · Radboud University Medical Center

Eligibility

Min Age
40 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-01
Primary Completion
2021-12-01
Completion
2021-12-01

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03489473 on ClinicalTrials.gov